A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf
.
The Future of Biosimilars and Biobetters in Ophthalmology
2022
touchREVIEWS in Ophthalmology
Biosimilars have been spreading widely in the field of ophthalmology since the patent expiry of innovator molecules. The patent of the ranibizumab innovator has already expired, and the aflibercept patent will expire in the next few years. India was the first country to launch the biosimilar of ranibizumab (Razumab, Intas Pharmaceuticals Ltd, Ahmedabad, Gujarat, India) in 2015, whose usage has increased over time. After the US Food and Drug Administration approval of ranibizumab's biosimilar,
doi:10.17925/usor.2022.16.1.6
fatcat:hybysgon7rab3kjjp4twue76l4